Alongside mixed Q2 results, Amgen's near future prospects are muddied by challenges in its anemia franchise: lowered guidance, increased regulatory scrutiny, and concerns over safety and reimbursement. Spaciously, the current climate is hostile, with»õuluier pressure stemming from the upcoming national coverage decision. However, the company's robust R&D pipeline and cost-saving efforts offer a glimmer of hope. The stock will likely remain volatile in the short term.

0